Carnosine And Anti-Ageing
Quick Read Carnosine is a small molecule your muscles naturally produce that declines with age. Research suggests it fights three
Subscribe to the distribution list, to get regular updates on supplement research for health,
🧠 NeuroBright Our evidence-based brain supplement formulated from 1.7M research papers
You’ve probably heard that omega-3 is good for your heart. Maybe you’re already taking a fish oil capsule every morning, feeling quietly virtuous about it. But what if the story is significantly more nuanced than “omega-3 = healthy heart tick”? What if the *type* of omega-3 you’re taking, the *dose*, and the specific reason you’re taking it all matter enormously — and most people are getting at least one of those things wrong? And what if one of the most important things omega-3 does in your body — lowering a dangerous blood fat called triglycerides — is something most people have barely heard of?
Triglycerides don’t get nearly the attention that cholesterol does. But elevated triglycerides are an independent cardiovascular risk factor, and a surprisingly common one, with rates rising in line with obesity and type 2 diabetes [8]. The good news: omega-3 fatty acids have one of the most well-established effects on triglyceride reduction in all of nutritional science. The complicated news: not all omega-3 supplements are created equal, the cardiovascular benefits go beyond just lowering triglycerides, and two major clinical trials managed to produce almost opposite results using what looked like similar interventions. Let’s untangle all of it.
*This post was produced with the help of VitacuityAI, which analysed 1.7 million research papers and selected the most relevant studies on this topic.*
First, a quick primer. Triglycerides are a form of fat that circulates in your blood. When you eat — particularly carbohydrates and fats — your body converts excess calories into triglycerides and stores them in fat cells. Between meals, hormones release these triglycerides to be used as energy. That’s normal. The problem arises when triglyceride levels stay persistently elevated.
Mild-to-moderate hypertriglyceridemia is defined as triglyceride levels of 200–499 mg/dL; very high is classified as ≥500 mg/dL [8]. Both categories are becoming more prevalent globally, driven largely by rising rates of obesity, diabetes, and poor dietary patterns [8]. And here’s why it matters for heart health: triglyceride-rich lipoproteins — the particles that carry triglycerides through your bloodstream — appear to be causal risk factors for coronary heart disease, contributing to what researchers call “residual cardiovascular risk”: the heart attack risk that remains even in people who are already on statins and have well-controlled LDL cholesterol [11].
So where do omega-3s come in? The two most studied omega-3 fatty acids are EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). Both are long-chain, very-long-chain polyunsaturated fatty acids found primarily in fatty fish and marine sources. Their triglyceride-lowering ability is one of the most consistently demonstrated effects in lipid research [14]. They work through several mechanisms: reducing the liver’s production of triglycerides, increasing the clearance of triglyceride-rich particles from the blood, and influencing the activity of enzymes involved in fat metabolism [4]. But — and this is important — EPA and DHA don’t appear to behave identically, and that distinction has become one of the most significant debates in cardiovascular nutrition science.
Evidence grade: Strong — multiple RCTs with consistent findings
The triglyceride-lowering effect of omega-3 is not subtle. In patients with very high triglyceride levels (above 500 mg/dL), approximately 4 grams per day of combined EPA and DHA has been shown to reduce triglyceride levels by around 45%, and to reduce very low-density lipoprotein (VLDL) cholesterol by more than 50% [4]. This is a substantial, clinically meaningful reduction.
Even at lower triglyceride levels — in the mild-to-moderate hypertriglyceridaemia range — omega-3 delivers meaningful results. A 2014 double-blind, parallel randomised trial of 93 adults with triglycerides between 150–499 mg/dL found that 2.4 grams per day of DHA and EPA (from either microalgal oil or fish oil) reduced triglycerides by approximately 19–23% compared to a corn/soy oil control, over 14 weeks [9]. Both the algae-derived and fish-oil-derived omega-3 performed comparably, which is relevant for people following plant-based diets who rely on algae-based supplements.
The American Heart Association, in a 2019 scientific advisory, confirmed that prescription omega-3 fatty acids at 4 g/day are “an effective and safe option for reducing triglycerides as monotherapy or as an adjunct to other lipid-lowering agents” [8]. This isn’t fringe nutrition science — it’s mainstream cardiology consensus.
Evidence grade: Conflicted — results diverge significantly depending on the omega-3 formulation used
Here’s where the story gets genuinely fascinating — and where many omega-3 headlines go wrong.
The REDUCE-IT trial (Reduction of Cardiovascular Events With EPA Intervention Trial) was a large randomised, placebo-controlled trial of high-dose EPA only (4 g/day of icosapent ethyl, a highly purified EPA formulation) in patients with elevated triglycerides who were already on statin therapy. The results were striking: a 25% reduction in major adverse cardiovascular events compared to placebo [8, 11]. That’s a substantial effect size in a population already taking statins.
The JELIS study, conducted earlier in Japan, found that EPA at 1.8 g/day significantly reduced cardiovascular events in patients with high cholesterol on statins — and the effect appeared independent of the degree of triglyceride reduction, hinting that EPA might be doing something beyond simply lowering blood fats [11].
But then came STRENGTH. This trial tested 4 g/day of a mixed EPA + DHA formulation in patients with high triglycerides — and found no significant reduction in cardiovascular events [7, 15]. Same high dose. Similar patient population. Opposite result.
How do we explain that? Researchers have proposed several possible explanations [13]: differences in the specific formulation (pure EPA vs. a mixed EPA/DHA product), differences in the placebo used (REDUCE-IT used mineral oil, which some argue may have inflated the apparent benefit by itself causing harm), differences in the ratio of EPA to DHA, and potentially distinct biological effects of EPA and DHA on inflammation, platelet aggregation, and plaque stability [12]. The honest summary: EPA-only formulations have the strongest cardiovascular outcome data, mixed EPA/DHA formulations have consistent triglyceride-lowering data but inconsistent cardiovascular outcome data, and we don’t yet fully understand why [13].
Evidence grade: Promising — human trial data exists, but mechanisms are still being mapped
The REDUCE-IT finding raised an important question: if EPA reduced cardiovascular events by 25%, but triglyceride levels only fell modestly in that trial, what else is EPA doing?
Research points to several additional mechanisms [12]:
– Anti-inflammatory effects: Omega-3 fatty acids, particularly EPA, appear to reduce systemic inflammation — a known driver of atherosclerosis (the plaque build-up in arteries that underlies most heart attacks and strokes). – Antithrombotic effects: EPA reduces platelet aggregation — in other words, it makes blood slightly less prone to clotting, which reduces the risk of a clot forming over an atherosclerotic plaque. – Endothelial function: Omega-3 appears to improve the health of the inner lining of blood vessels. – Plaque stabilisation: Some research suggests omega-3 may influence the composition and stability of coronary plaques, potentially making them less likely to rupture [12]. – Blood pressure reduction: A modest but documented antihypertensive effect has been observed [12].
This matters for everyday supplement users, because it means the benefits of omega-3 for heart health are likely not *only* about the number on your triglyceride test. Even if your triglycerides are in the normal range, there may be broader cardiovascular and anti-inflammatory reasons to maintain adequate EPA and DHA intake.
Evidence grade: Strong on the principle; specific comparisons are an active area of research
This is perhaps the most practically important finding for anyone buying omega-3 supplements. The research makes clear that prescription-grade omega-3 formulations and over-the-counter supplements are not interchangeable — and not just for regulatory reasons.
Dietary supplements are not subject to the same government standards for safety, efficacy, and purity as prescription drugs. They may contain variable concentrations of EPA and DHA and potentially other contaminants [14]. The active dose in many over-the-counter fish oil capsules is far lower than the doses used in clinical trials. A typical 1,000 mg fish oil capsule may contain only around 300 mg of combined EPA and DHA — meaning you would need 6–13 standard capsules per day to reach the 2–4 g/day threshold used in the key triglyceride-lowering studies [4].
There is also an important distinction between EPA-only and EPA+DHA formulations. Prescription products containing both EPA and DHA have been shown to lower triglycerides effectively — but they may also increase LDL cholesterol in some patients, particularly those with very high baseline triglycerides [8, 14]. EPA-only prescription formulations did not show this LDL-raising effect [8]. This is clinically relevant for patients already managing high LDL alongside high triglycerides.
The 2019 American Heart Association advisory is explicit on this point: “evidence obtained from highly purified forms should not be extrapolated to other mixed formulations, including over-the-counter omega-3 supplements” [13]. That’s not a reason to abandon supplements — but it is a reason to be thoughtful about what you’re taking, at what dose, and why.
Evidence grade: Promising — one well-designed RCT, consistent with fish oil data
For vegetarians, vegans, or anyone who prefers not to take fish-derived supplements, the 2014 microalgal oil trial is reassuring [9]. In a 14-week, double-blind, randomised trial of 93 adults, an algae-derived oil providing 2.4 g/day of DHA and EPA reduced triglycerides by approximately 19% — a result statistically indistinguishable from standard fish oil, and both significantly outperformed the corn/soy oil control.
Fish get their EPA and DHA from the marine algae they eat — so going directly to the algae source removes the fish from the equation without, apparently, removing the benefit. This is a relatively small and short trial, so we shouldn’t over-claim — but it aligns well with the mechanistic logic and the broader triglyceride-lowering evidence base.
The omega-3 story is genuinely one of the most contested in cardiovascular medicine, and intellectual honesty requires sitting with several unresolved questions.
The REDUCE-IT controversy: The 25% reduction in cardiovascular events in REDUCE-IT remains debated. Critics have pointed out that the placebo used — mineral oil — may itself have had negative cardiovascular effects, potentially inflating the apparent benefit of EPA by comparison. The true effect size of EPA-only supplementation on cardiovascular outcomes remains uncertain [13, 15].
EPA vs. DHA — what’s the real difference? We know EPA-only formulations have the strongest cardiovascular outcome data. We don’t yet fully understand *why*. Is DHA neutral, or might it actually counteract some of EPA’s protective effects at high doses? This is an active and unresolved research question [13].
Atrial fibrillation risk: Both REDUCE-IT and STRENGTH reported an increased prevalence of atrial fibrillation (an irregular heart rhythm) in participants taking high-dose omega-3 [15]. This is a genuine safety signal that cannot be dismissed. It doesn’t apply to typical supplement doses, but it is a meaningful consideration at the 4 g/day prescription doses used in these trials.
Long-term data at supplement doses: Most of the strong mechanistic and triglyceride-lowering data comes from trials of 2–4 g/day over 12–16 weeks. We have less data on the long-term effects of the lower doses (typically 0.5–1 g/day EPA+DHA) that most people actually take as everyday supplements.
Who benefits most? The cardiovascular outcome benefits in REDUCE-IT and JELIS were seen primarily in secondary prevention — people who already had cardiovascular disease or were at very high risk [3, 12]. The benefit in primary prevention (people without established disease) is less clear.
Residual uncertainty on mechanisms: The fact that triglyceride reduction in some trials didn’t fully account for the cardiovascular benefit suggests omega-3’s protective mechanisms are not yet fully mapped [12]. More research is needed before we can say with confidence exactly *how* EPA reduces cardiovascular risk.
Let’s think about this practically. What should an intelligent, health-conscious person in their 40s, 50s or 60s actually do with all of this?
If you don’t know your triglyceride level, it’s worth finding out. A standard lipid panel from your GP includes triglycerides, and it’s one of the most informative numbers you can know. Triglycerides are highly responsive to diet, exercise, alcohol intake, and body weight — so there’s a lot you can do about them. If yours are elevated, omega-3 is one of the best-evidenced nutritional interventions available.
At typical supplement doses (500 mg–1 g/day EPA+DHA), the evidence for general cardiovascular and anti-inflammatory benefit is reasonable, the safety profile is excellent, and EPA and DHA are genuinely difficult to obtain in adequate amounts from diet alone unless you’re eating fatty fish multiple times a week. Omega-3 fatty acids are water-insoluble but the excess is not stored in a way that causes toxicity at normal supplement doses — this is not a fat-soluble vitamin that accumulates to dangerous levels. Daily supplementation is a safe, practical default for most people.
If you’re specifically targeting elevated triglycerides, the evidence points clearly towards needing higher doses — 2–4 g/day of EPA+DHA — to achieve the 20–45% reductions seen in clinical trials [4, 8, 9]. At those doses, it’s worth having a conversation with your doctor, particularly given the atrial fibrillation signal observed in high-dose prescription trials [15].
Pay attention to what’s in your supplement. Check the label for actual EPA and DHA content, not just total fish oil weight. A high-quality product from a reputable manufacturer matters — purity and concentration vary significantly between over-the-counter products [14]. If you follow a plant-based diet, algae-derived omega-3 appears to be as effective as fish oil for triglyceride reduction [9].
Don’t expect omega-3 to do it alone. Triglycerides respond meaningfully to reducing refined carbohydrates and sugar, limiting alcohol, increasing physical activity, and managing body weight. Omega-3 works best as part of a broader approach, not as a substitute for it.
The bottom line: omega-3’s effect on triglycerides is one of the most robustly evidenced findings in nutritional science. The cardiovascular benefit picture is genuinely more complicated — but the overall arc of the evidence points towards EPA, at meaningful doses, being genuinely protective for people at elevated cardiovascular risk. For most people reading this, a daily omega-3 supplement is a low-risk, evidence-supported habit. The question is whether you’re taking enough of the right kind.
[1] Hypertriglyceridemia. (2008). https://pubmed.ncbi.nlm.nih.gov/18199874/
[2] A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review”. (2020). DOI: 10.1007/s12325-020-01420-z | https://pubmed.ncbi.nlm.nih.gov/32647913/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444398/
[3] Triglycerides and Cardiovascular Outcomes — Can We REDUCE-IT? (2020). DOI: 10.1055/s-0040-1701639 | https://pubmed.ncbi.nlm.nih.gov/32132810/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054063/
[4] Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. (2007). https://pubmed.ncbi.nlm.nih.gov/17461707/
[5] Triglyceride lowering drugs: not just icosapent ethyl. (2020). DOI: 10.1093/eurheartj/ehaa075 | https://pubmed.ncbi.nlm.nih.gov/32154875/
[6] Icosapent Ethyl Supplementation and Cardiovascular Prevention — Implications of Evolving Data. (2022). DOI: 10.1001/jamacardio.2022.3701 | https://pubmed.ncbi.nlm.nih.gov/36287555/
[7] Omega-3 Polyunsaturated Fatty Acids in Patients with Hypertriglyceridemias and Atherosclerosis. (2021). DOI: 10.18087/cardio.2021.6.n1578 | https://pubmed.ncbi.nlm.nih.gov/34311692/
[8] Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. (2019). DOI: 10.1161/CIR.0000000000000709 | https://pubmed.ncbi.nlm.nih.gov/31422671/
[9] A new, microalgal DHA- and EPA-containing oil lowers triacylglycerols in adults with mild-to-moderate hypertriglyceridemia. (2014). DOI: 10.1016/j.plefa.2014.07.012 | https://pubmed.ncbi.nlm.nih.gov/25123060/
[10] PURL: Consider this Rx for patients with high triglycerides? (2020). https://pubmed.ncbi.nlm.nih.gov/33348346/
[11] Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction. (2020). DOI: 10.1007/s11883-020-00893-1 | https://pubmed.ncbi.nlm.nih.gov/33009961/
[12] Omega-3 Fatty Acids and Coronary Artery Disease: More Questions Than Answers. (2021). DOI: 10.3390/jcm10112495 | https://pubmed.ncbi.nlm.nih.gov/34200081/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201167/
[13] Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis. (2022). DOI: 10.1007/s11883-022-01031-9 | https://pubmed.ncbi.nlm.nih.gov/35499805/
[14] Overview of omega-3 Fatty Acid therapies. (2013). https://pubmed.ncbi.nlm.nih.gov/24391388/
[15] High-dose Omega-3 for cardiovascular prevention, a bad idea? (2022). DOI: 10.53738/REVMED.2022.18.772.434 | https://pubmed.ncbi.nlm.nih.gov/35266343/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Carnosine is a small molecule your muscles naturally produce that declines with age. Research suggests it fights three
Quick Read CoQ10 is a molecule found in your cells’ power stations (mitochondria) that helps convert food into energy your
